/
Jin Medical International Ltd. designs, develops, manufactures and markets wheelchairs and rehabilitation medical equipment for people with disabilities, the elderly and individuals recovering from injury. The company's product portfolio includes manual and electric wheelchairs, wheelchair components, walking aids, oxygen concentrators, micro-hyperbaric oxygen chambers and nano-thermal bathing equipment. Jin Medical also offers lifestyle beauty and health devices, shampoo instruments and shared wheelchair infrastructure to support mobility and daily living needs. The company operates manufacturing facilities in Changzhou, Taizhou and Chuzhou across Jiangsu and Anhui provinces in China, serving markets across mainland China, Japan, the United States, Hong Kong, Singapore, Korea and Australia. Founded in 2006 and headquartered in Changzhou, China, Jin Medical positions itself as an industrial leader in assistive technologies and rehabilitation equipment, emphasizing research and development to drive product innovation and expand its presence in rehabilitation and health-related markets globally.
$1.90
+$0.00 (+0.00%)
Live · 05:23 PM
Operating margin is thin at 2.94%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 12.0% YoY. Margins deteriorated 12.5pp alongside, both lines moving the wrong way.
ROIC dropped from 8.72% to 1.19%, capital efficiency is deteriorating. Negative free cash flow of -$4M. The business is consuming cash, not generating it.
11.8x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$21M
▼ -12.0% YoY
Net Income (TTM)
$1M
▼ -59.6% YoY
Op. Margin
2.94%
▼ -12.5pp YoY
ROIC
1.19%
▼ -7.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▼ -59.8% YoY
Op. Cash Flow (TTM)
$4M
▲ +713.8% YoY
Net Debt
-$11M
Net Cash Position
Cash & Equiv.
$30M
3Y CAGR: +2.5%
Continue Research
At a P/E of 11.8, Jin Medical International (ZJYL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Jin Medical International scores 37/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Jin Medical International scores 37 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.9% operating margin and a 1.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ZJYL's valuation and scores 37/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.